SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare > Medizone Intl. (MZEI)

info post for new investors of MZEI, Medizone

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
goforthebet Member Profile
Member Level 
Followed By 369
Posts 35,436
Boards Moderated 7
Alias Born 05/11/08
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/19/2016 5:26:44 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/10/2016 2:06:01 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 11/4/2016 12:20:03 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/27/2016 6:04:08 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/7/2016 9:30:51 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/30/2016 12:46:59 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 8/25/2016 8:31:26 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 8/19/2016 5:21:41 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/19/2016 5:19:24 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/15/2016 1:50:32 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 8/5/2016 8:03:24 AM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 8/4/2016 5:27:07 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 7/25/2016 5:21:04 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/12/2016 8:18:39 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/25/2016 11:20:53 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/13/2016 2:00:23 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/6/2016 4:48:46 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 5/6/2016 4:01:23 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 3/3/2016 9:19:24 AM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 2/16/2016 2:35:25 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 2/16/2016 12:48:28 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 2/16/2016 10:48:30 AM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 2/12/2016 5:58:00 PM
goforthebet Member Level  Monday, 07/29/13 09:15:42 AM
Re: None
Post # of 43035 
info post for new investors of MZEI, Medizone International Inc

In 2008 Ed Marshall started together with DR.Mike Shannon, one of the most respected sientists etc of Canada a new venture with ozon treatment for hospital rooms and other needs, called AsepticSure.

See Dr. Shannons Bio

Michael E. Shannon, M.A.,M.Sc.,M.D. - President & Director of Medical Affairs, Board Member

Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years.

He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces.

In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.

In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General’s office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004.

Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.

Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.

Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health.

Together with Dr. Dick Zoutamn (see his bio here below, one of the most respected infection desease scientist/doc worldwide) he developed Asepticsure

Dick Zoutman M.D., FRCPC

Chief Medical Officer, Medizone International Inc.

Dr. Dick Zoutman has been Chief Medical Officer at Medizone International Inc., since June 2012. Dr. Zoutman provides input into the design, planning, initiation and analysis of all beta test and post market surveillance programs worldwide. Dr. Zoutman also provides direct liaison with clinical investigators and maintaining professional awareness of Medizone's many scientific accomplishments through the preparation of peer reviewed articles and the preparation of presentations at medical conferences. Dr. Zoutman served as a consultant at Medizone for over two years

Look at this videos

here the highlights and where we stand now

May 10, 2011 we have got the peer Review

Hospital Acquired Infections Breakthrough: AsepticSure™ Disinfection Technology Receives Glowing Peer Review - See more at:


July 7, 2011 we got one of 3 awards from the WHO

AsepticSure™ Hospital Disinfection System Wins International Acclaim from World Health Organization - See more at:

November 29, 2011 we have got our patent issued in Canada.

Medizone’s lead patent was granted on November 22, 2011 by the Canadian Intellectual Property Office (patent office) for processes and systems relating to the platform technology.
Canadian Patent Issued To Medizone International For AsepticSure™ Disinfection Technology - See more at:

January 9, 2012 filings of its recently granted lead patent application (Canadian Patent No 2735739) have been completed in the United States, Mexico, Brazil, China and Japan.

AsepticSure Patent Protection Program Expanded – Superbugs In Five Countries Get Nervous - See more at:

February 8, 2012 AsepticSure Patent Protection Goes Global

has now completed National patent application filings of its recently granted lead patent application (Canadian Patent No 2735739). These filings apply to the United States, Mexico, Brazil, China, Japan, Korea, Singapore, the 37 countries of the European Patent Organization (EU), Great Britain, India and Australia - See more at:

June 7, 2012 Dr. Dick Zoutman and Glen Balzer join the Team

Dr Dick Zoutman, and Californian management consultant, Mr. Glen Balzer, will join its management team. The Company views this double-acquisition as a massive boost to its corporate strength as it readies itself for dramatic growth into the world arena of infection control. - See more at:

June 12, 2012 100% killing rate with tuberculosis

Tuberculosis Breakthrough – New Technology To Greatly Reduce Deadly Disease Risk In Hospitals - in achieving 100% kill rates with TB in three successive trials, it had achieved another important milestone in its understanding of the antimicrobial limits of its recently launched hospital disinfection technology, AsepticSure™. - See more at: more at:

February 6, 2013 Mzei got the patent in Singapore granted

Singapore Patent Opens Door to Asia For Revolutionary Hospital Disinfection Technology - See more at:

February 14, 2013 Hospital trial porving success in Canadian Hospital

AsepticSure Disinfection System Proving Successful In Canadian Hospital Trials - See more at:

April 11, 2013 partneringwith Sani Mrc Wood Wyant, a Canadian giant in the sanitation market

Hospital disinfection technology, AsepticSure, to be distributed nation-wide by Wood Wyant, Canada’s largest distributor of sanitation products - See more at:


The United States Food and Drug Administration has ruled AsepticSure to be considered a Class 1 medical device. That ruling was in keeping with the expectations of our Regulatory Team. We are pleased with this FDA determination. The path forward is clear.

The final hurdle (as we see it) to acceptance of AsepticSure as a disinfection system, and thus clearance to introduce AsepticSure into the US Market, is approval by the Environmental Protection Agency. At the request of the EPA, a meeting has been scheduled for late May in Washington. The three senior leaders of our Regulatory Team including Drs Shannon and Zoutman will attend. While we cannot predict with certainty, our expectation is that regulatory approval by the EPA will be forthcoming in the weeks following that meeting.

- See more at:

So we have the FDA approval, we are waiting on the EPA and the us patent, which both should be issued in 2013 imo.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist